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Abstract
In contrast to HIV infection in humans and SIV in macaques, SIV infection of natural hosts including sooty mangabeys (SM) is
non-pathogenic despite robust virus replication. We identified a novel SM CCR5 allele containing a two base pair deletion
(D2) encoding a truncated molecule that is not expressed on the cell surface and does not support SIV entry in vitro. The
allele was present at a 26% frequency in a large SM colony, along with 3% for a CCR5D24 deletion allele that also abrogates
surface expression. Overall, 8% of animals were homozygous for defective CCR5 alleles and 41% were heterozygous. The
mutant allele was also present in wild SM in West Africa. CD8+ and CD4+ T cells displayed a gradient of CCR5 expression
across genotype groups, which was highly significant for CD8+ cells. Remarkably, the prevalence of natural SIVsmm
infection was not significantly different in animals lacking functional CCR5 compared to heterozygous and homozygous
wild-type animals. Furthermore, animals lacking functional CCR5 had robust plasma viral loads, which were only modestly
lower than wild-type animals. SIVsmm primary isolates infected both homozygous mutant and wild-type PBMC in a CCR5-
independent manner in vitro, and Envs from both CCR5-null and wild-type infected animals used CXCR6, GPR15 and GPR1 in
addition to CCR5 in transfected cells. These data clearly indicate that SIVsmm relies on CCR5-independent entry pathways in
SM that are homozygous for defective CCR5 alleles and, while the extent of alternative coreceptor use in SM with CCR5 wild
type alleles is uncertain, strongly suggest that SIVsmm tropism and host cell targeting in vivo is defined by the distribution
and use of alternative entry pathways in addition to CCR5. SIVsmm entry through alternative pathways in vivo raises the
possibility of novel CCR5-negative target cells that may be more expendable than CCR5+ cells and enable the virus to
replicate efficiently without causing disease in the face of extremely restricted CCR5 expression seen in SM and several other
natural host species.
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Introduction
HIV-1 emergence into the human population resulted from
cross-species transmission of SIVcpz from chimpanzees (Pan
troglodytes), which itself resulted from transmission and subsequent
recombination of SIVs infecting primates on which chimpanzees
prey [1,2]. Similarly, both simian AIDS caused by SIVmac/smm
in rhesus macaques (RM; Macaca mulatta) and HIV-2 infection of
humans originated from cross-species transmission of SIVsmm
from naturally infected sooty mangabeys (SM; Cercocebus atys)
[3,4,5]. In marked contrast to pathogenic infections leading to
AIDS in non-natural hosts, infection in natural host species
including SM is typically non-progressive [6,7,8]. Importantly, the
benign nature of SM infection in vivo is not due to overall restricted
viral replication, as both nonpathogenic natural host and
pathogenic nonnatural host infections are characterized by robust
viremia [9,10,11,12]. This observation indicates that immunode-
ficiency virus replication and pathogenesis are not inextricably
linked. Thus, understanding natural host infection has become a
high priority for identifying key features of infection in vivo that
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regulate pathogenesis and, potentially, identify opportunities to
modulate disease apart from or in addition to suppressing overall
virus replication through pharmacologic or immune mechanisms.
HIV and SIV entry into target cells is initiated by binding of the
viral envelope glycoprotein (Env) to cell surface CD4, followed by
structural changes that enable interactions with a seven trans-
membrane G protein coupled cell surface receptor that then
triggers fusion. HIV-1 isolates use CCR5 or CXCR4 or both, and
in vitro use other molecules infrequently. The restricted expression
of CCR5 mainly on memory CD4+ T cells, but broader
expression of CXCR4 on both memory and naı¨ve subsets, is
thought in part to underlie the accelerated disease progression seen
in individuals in whom CXCR4-using HIV-1 variants emerge late
in the course of infection [13,14,15,16]. In contrast, SIV strains
use CCR5 almost universally and very rarely use CXCR4. Sooty
mangabeys express very low levels of CCR5 on their CD4+ T
cells, a mechanism by which replication might be regulated in vivo
and restrict transmission and pathogenesis [17,18]. However, most
strains of SIV use a number of other alternative coreceptors in in
vitro assays, such as CXCR6 (STRL33), the orphan receptors
GPR1 and GPR15, and several others [19,20,21]. Despite the
efficient use of such alternative entry pathways by SIVmac and
SIVsmm isolates in transfected cells, infection and cell targeting in
vivo is generally thought to be dependent on CCR5 [22]. Notably,
however, the proportion of CD4+ T cells depleted and/or infected
at a given time in macaques and mangabeys may exceed the
proportion of cells with detectable CCR5 expression, raising the
possibility that other pathways in addition to CCR5 might be
utilized [23,24].
Although both natural and non-natural host infections result in
high level virus replication, several distinguishing features provide
clues as to possible causes for the distinct outcomes. It is long
believed that in addition to CD4+ T cell destruction, pathogenesis
involves an inability to effectively replenish these populations
[25,26]. In pathogenic rhesus macaque infection, damage to the
CD4+ T central memory (Tcm) subpopulation appears to play a
central role in the inability of infected animals to replenish CD4+
T effector and effector memory (Tem) cells depleted by infection
[27]. It has been recently found that cell-associated viral loads in
CD4+ Tcm are considerably lower in SM than RM, despite
equivalent or higher Tem infection levels, which might enable
better immune cell homeostasis in infected SM (G.S. and M.P;
unpublished observations). Another difference is the presence of
chronic generalized immune activation in infected humans and
RM, whereas natural hosts display generalized immune activation
during acute infection that then rapidly resolves [11,28,29,30].
Chronic generalized immune activation may contribute to
accelerated T cell turnover and ultimate depletion, and is believed
to result in large part from translocation of gut microbial products
due to gastrointestinal barrier damage during acute infection [31].
However, vigorous virus replication and extensive CD4+ T cell
depletion in gut mucosal tissue occur in both natural and non-
natural hosts [24,32,33,34]. A potentially important difference is
Th17 CD4+ T cells, which play a critical role in defense against
bacteria at mucosal sites, and are lost in HIV-1 and SIVmac
rhesus macaque infection but spared in infected natural hosts
[35,36,37,38]. Thus, the factors regulating CD4+ T cell subset
targeting in vivo may be central to defining the outcome of infection
in natural or non-natural hosts.
Interestingly, evolution appears to have favored mutations in
the CCR5 gene that abrogate surface expression of this molecule.
An allele containing a 32 base pair frameshift deletion in human
CCR5 that abrogates cell surface expression (CCR5D32) is present
at a frequency of 10% in the Caucasian population, resulting in
about 18% heterozygous and 1% homozygous individuals. CD4+
cells from individuals homozygous for CCR5D32 are resistant to
infection by CCR5-using HIV-1 isolates in vitro but permissive for
strains that can use CXCR4, and the essential role for CCR5 in
HIV-1 transmission and infection is demonstrated by the finding
that individuals homozygous for CCR5D32 are highly resistant to
infection [39,40]. Furthermore, heterozygous individuals can be
infected but show lower viral loads and slower disease progression,
in association with lower levels of CCR5 expression [41,42]. Red-
capped mangabeys (RCM; Cercocebus torquatus) are the natural host
of SIVrcm, and a 24 base pair in-frame deletion (CCR5D24) that
also abrogates surface expression is present at an allelic frequency
of 87% [43]. As a result, $70% of RCM are homozygous for the
mutation and do not express CCR5, and the one known exception
to exclusive CCR5 dependence by SIV in vivo is SIVrcm, which
uses CCR2b for entry and cannot use CCR5. The same
CCR5D24 mutant allele was also reported in two different
populations of SM, which are closely related to RCM, but with a
low allelic frequency of 4% and no animals homozygous for the
allele were found [43,44].
In this study, we identified a novel 2 base pair deletion and
frameshift mutation in SM CCR5 (CCR5D2) that results in a lack
of surface expression and coreceptor function. The mutation is
present at a 26% allele frequency in the large Yerkes National
Primate Research Center (YNPRC) SM colony, and together with
the previously-described D24 allele results in 8% of animals
lacking functional CCR5. However CCR5-null SM are susceptible
to natural and experimental SIVsmm infection and exhibit robust
viral replication. This is the first clear evidence for in vivo
alternative coreceptor use by SIVsmm in its natural hosts, which
provides an explanation for the efficient use of alternative
coreceptors by the SIVsmm/mac family of viruses. This data also
suggests that cell targeting and tropism in sooty mangabeys is
linked to expression and use of both CCR5 and additional
alternative entry pathways, and identifies a third example of
convergent evolution resulting in nonfunctional mutant CCR5
alleles among primate species.
Author Summary
SIV causes AIDS in macaques, like HIV-1 does in humans,
but not in its natural host species such as sooty
mangabeys (SM). It is therefore important to understand
infection in natural hosts, including the mechanisms and
cellular targets of infection. SIV replication in SM is thought
to exclusively use CCR5 as its entry coreceptor, which
mediates viral entry in conjunction with CD4 and is the
main determinant of target cell tropism. However, other
molecules also function as SIV coreceptors in vitro. We
discovered that inactivating mutations in the CCR5 gene
are common among SM and, furthermore, homozygous
mutant animals lacking functional CCR5 still become
infected and have high viral loads. Ex vivo, SM lymphocytes
can be infected independently of CCR5, and several
alternative entry coreceptors are used by SIV from both
CCR5+ and CCR5-null animals. Thus, SIV infection in SM is
mediated by other coreceptors in addition to CCR5,
suggesting that these molecules together may determine
tropism and cell targeting in vivo. These results provide
new insight into an important model of nonpathogenic
natural host infection, and identify a novel role for
alternative entry pathways suggesting a potentially
broader range of target cells in vivo than currently
recognized.
SIV Infection of CCR5-Null Sooty Mangabeys
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Results
Identification of a novel mutation in the sooty mangabey
CCR5 gene
We amplified the CCR5 coding sequence from SM genomic
DNA, cloned it into an expression vector and analyzed several
clones by sequence analysis. Cloning from four independent PCR
reactions amplifying smCCR5 from one animal (FVq) resulted in
the identification of two distinct alleles in each of the PCR
amplifications (Figure 1). One was a wild-type allele, similar to
published smCCR5 sequences (smCCR5 wt), and the other was a
novel allele containing a two base pair deletion at nucleotides 466
and 467 of the coding sequence (smCCR5D2), which corresponds
to the fourth transmembrane domain (TM4) of the smCCR5
protein (Figure 1A). This deletion causes a frameshift that results in
a predicted protein with 110 missense amino acids prior to
termination at residue 265 (Figure 1B). In addition to this deletion,
the smCCR5D2 allele contains two nucleotide substitutions
compared with the wild-type allele identified. The first is a
436T.G substitution resulting in a L146V amino acid change,
which is also found in several published wild-type smCCR5
sequences. The second nucleotide substitution is 538C.T, but is
masked in CCR5D2 due to the frameshift.
In addition to premature truncation of the protein, the mutation
results in several charged amino acids predicted within TM4, as
well as loss of both disulfide bonds (between the N-terminus and
third extracellular loop (ECL), and between the first and second
ECLs, respectively) that maintain secondary structure. These
features suggest that the mutant protein is unlikely to be
configured in a manner to allow proper membrane placement
and either normal signaling or SIV/HIV entry coreceptor
function.
There are several other mutations in primate CCR5 genes,
including the well-studied 32 base pair frameshift mutation in
human CCR5 (CCR5D32) [39,40,42] and a 24 base pair deletion
(CCR5D24) that is common in RCM and also reported at low
frequency in SM [43,44]. Therefore, we examined the relationship
between this SM CCR5D2 deletion and the D24 RCM/SM and
human D32 deletions (Figure 1A & B). The smCCR5D2 deletion
occurs in the same region of TM4, and overlaps the D24 deletion,
which is characterized by multiple G-T-G repeats. In contrast, the
human CCR5D32 deletion occurs approximately 90 bases
downstream of smCCR5D2, within the second extracellular loop
of the protein. Interestingly, the SM and RCM D24 alleles also
contain the 436T.G and 538C.T substitutions seen
smCCR5D2, which result in amino acids identical to those in
human CCR5 at those respective sites (valine at position 146 and
serine at position 180; Figure 1B).
Because the CCR5D24 mutation was previously reported to be
present in animals at YNPRC [44], animals were screened for its
presence by PCR and several D24 carriers were identified (Figure
S1). We therefore generated a clone of the CCR5D24 coding
region by PCR of genomic DNA from one heterozygous animal.
Sequence analysis of this CCR5D24 clone was similar to the
sequence previously described [43,44], except for a non-coding
1026G.T substitution.
Cell surface expression of mutant smCCR5D2
Previous studies have shown that proteins encoded by the
mutant human CCR5D32 and RCM/SM CCR5D24 are not
expressed on the cell surface [40,44]. To test whether the
smCCR5D2 mutant gene gave rise to a protein expressed on the
cell surface, we transfected 293T cells with wild-type and mutant
SM CCR5 expression plasmids, along with human CCR5, and
measured surface expression by flow cytometry. Staining utilized
mAb 3A9, which cross-reacts with both human and SM CCR5
and, importantly, recognizes an epitope in the N-terminus that is
upstream of the mutation and should be detected if the predicted
protein were expressed.
As shown in Figure 2, surface expression of CCR5 was readily
detected on cells transfected with SM or human wild-type CCR5.
In contrast, neither the D2 nor D24 SM mutant CCR5 alleles gave
rise to detectable surface expression. We have so far been unable
to assess intracellular expression because of high nonspecific
intracellular staining with 3A9 and other anti-N-terminal CCR5
antibodies in all cells tested so far (data not shown). From this data,
we conclude that the frameshift mutation in smCCR5D2 results in
a truncated protein that is not expressed on the cell surface. In
addition, our observation that the CCR5D24 mutant allele is not
expressed at the cell surface is consistent with previous reports that
this deletion abrogates cell surface expression even though it is not
a frameshift [43,44]. We also asked if the mutant protein might
have a dominant negative effect on wild-type CCR5 expression,
but found no change in CCR5 staining if the wild-type CCR5
plasmid was co-transfected along with the D2 or D24 alleles
(Figure S2).
Prevalence of the smCCR5D2 allele in the YNPRC sooty
mangabey population
Next we determined the prevalence of the smCCR5D2 allele in
SM housed at the Yerkes National Primate Research Center
(YNPRC), which is the largest captive colony of SM in the world
(n = 202). All animals were initially screened using a discriminatory
PCR assay that specifically identifies the smCCR5 wild-type and
D2 alleles (Figure S1A). Animals were also screened for the D24
allele using primers that discriminate D24 from D2 and wild-type
alleles based on amplicon size (Figure S1B). Results were then
verified by direct bulk sequencing of genomic DNA amplicons that
confirmed the presence or absence of homozygous genotypes, or
demonstrated frameshifting with sequence overlap in heterozygous
animals (Figure S1C).
The result from this analysis is shown in Table 1. Five of six
possible genotypes were identified: 50.5% of the SM carried two
wild-type CCR5 alleles; 37.6% were heterozygous for wild-type
and D2 alleles, and 4% of the SM were heterozygous for the wild-
type and D24 alleles. Notably, 6.4% of the SM were homozygous
for the smCCR5D2 allele, and 1.5% carried both D2 and D24
mutant alleles (Table 1). Thus, nearly 8% of animals carry two
CCR5 mutant alleles encoding defective CCR5 proteins. We did
not identify any SM that were homozygous for the D24 allele.
In this SM population, analysis of allelic frequencies showed
26% of alleles carried the novel D2 deletion, 3% carried the D24
deletion, and 71% were wild-type. Of note, the 3% frequency we
found for the D24 allele is similar to the 4% allelic frequency
described 12 years ago among SM housed at YNPRC [44]. We
then used the allelic frequencies to calculate a predicted genotype
distribution (Table 1 and Table S1). There was close agreement
between predicted and observed genotypes (p = ns; Chi-square
test), suggesting that the CCR5 alleles are in equilibrium in this
population (of which,60% are SIV-infected), without evidence of
selective pressure favoring or disfavoring any of the genotypes.
Prevalence of mutant CCR5 alleles in other captive and
wild African sooty mangabey populations
The YNPRC colony is the largest population of SM in the US
and the close match between predicted and observed CCR5
genotype distributions suggested an absence of selective pressure
SIV Infection of CCR5-Null Sooty Mangabeys
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Figure 1. Sequence alignment of wild-type and mutant CCR5 genes. (A) Partial nucleotide sequence alignment and (B) predicted protein
sequence alignment of the wild-type smCCR5 and smCCR5D2 alleles (GenBank HM246693 and HM246694), the CCR5D24 alleles previously
described in sooty and red capped mangabeys (GenBank AF07473 and AAC62474), and human wild-type CCR5 and CCR5D32 alleles (GenBank
DQ217934 and U66285). Residues identical to the wild-type smCCR5 molecule are indicated by ‘.’ and gaps are shown as dashes. Location of the
frameshift resulting from the smCCR5D2 deletion in TM4 is indicated by an inverted black triangle while the huCCR5D32 frameshift is indicated by
SIV Infection of CCR5-Null Sooty Mangabeys
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for or against any specific genotype. However, we wished to
determine the frequency with which these alleles and genotypes
were present in other SM populations, so we analyzed genomic
DNA obtained from 29 animals housed at the Tulane National
Primate Research Center (TNPRC). Of note, many of the
monkeys that founded the TNPRC colony originally came from
YNPRC in the 1980s, but have been housed and bred separately
since then. In this smaller population the D2 allele was present at a
frequency of 19% and the D24 allele had a frequency of 5%. As
shown in Table 2 and Table S2, the observed genotype
frequencies in this population also do not differ from those
predicted by allele frequencies.
We also asked whether the CCR5D2 allele was present in SM in
Africa. For this analysis we amplified CCR5 genes from fecal-
derived host DNA samples from 33 wild-living animals in the Tai
forest of Cote d’Ivoire [45]. Five animals carried both the
CCR5D2 and wild-type alleles, and in one animal only the D2
allele was detected. An additional 2 animals carried both D24 and
wild-type alleles, while the remaining animals revealed only wild-
type sequences. Because this analysis utilized fecal DNA
containing limiting quantities of host DNA, we can only be
certain that both alleles were captured if animals were found to be
heterozygous. Thus, while it is not possible to determine a precise
allele frequency, these genotypes suggest a minimum allele
frequency of 9% for CCR5D2 and 3% for CCR5D24 in this
population. This result indicates that the D2 allele is also present in
wild-living SM in Cote d’Ivoire, although likely at a lower
frequency than in captive animals at YNPRC.
Expression of CCR5 on SM CD4+ and CD8+ T cells ex vivo
Since overexpression studies in transfected cells suggested that
neither this common smCCR5D2 nor the less common D24
proteins are expressed on the cell surface, we examined the
relationship between genotypes and CCR5 expression on primary
SM CD4+ and CD8+ T cells. To address this point, we analyzed
CCR5 expression data that was available from animals housed at
the YNPRC collected during periodic surveys between 2004 and
2009, focusing on uninfected animals, and grouped individuals
according to their CCR5 genotypes. Since neither D2 nor D24
CCR5 alleles express following transfection, the two mutations
were combined for the purposes of this analysis into a homozygous
wild-type, heterozygous, and homozygous deletion allele groups
(Figure 3).
As previously reported [18] and as shown in Figure 3, CCR5
expression is markedly greater on SM CD8+ T cells than CD4+ T
cells. In both populations there was a gradation in the percentage
of cells staining positive for CCR5 that correlated with CCR5
genotype status. The difference was particularly evident for CD8+
T cells, and the percentage of CCR5+/CD8+ T cells was 9.9%,
5.4% and 0.8% for wild-type, heterozygous and homozygous
mutant groups, respectively (Figure 3A; p,0.0001 by Kruskal-
Wallis test). This finding indicates that the CCR5D2 genotype acts
as a determinant of CCR5 expression on CD8+ T cells. There was
also a strong linear relationship between wild-type gene dosage
and CCR5 expression for CD8 cells (R2= 0.99996; p = 0.009 by
Pearson’s 2-tailed correlation coefficient), consistent with the
absence of a dominant negative effect by the mutant alleles in
transfected cells (Figure S2). A trend was also evident for CCR5
staining on CD4+ T cells among the three groups (2.8%, 1.7%
and 1.2% in the wild-type, heterozygous and homozygous mutant
groups, respectively), which did not reach statistical significance
(p = ns by Kruskal-Wallis test) but is consistent with the notion
that, although overall very low, CCR5 expression on CD4+ T cells
is also regulated by CCR5 genotype.
Representative FACS plots showing CCR5 expression on
CD4+ and CD8+ T cells from a homozygous wild-type,
heterozygous and homozygous mutant animal are shown in
Figure 3B. We think the low level (,1%) of cells within the CCR5
gate for homozygous mutant animals likely represents background
staining, rather than low levels of N-terminal expression given the
result of transfection studies (Figure 2). Unfortunately, antibodies
available that are directed at other epitopes in human CCR5 do
not recognize SM CCR5.
CCR5-null genotype does not protect sooty mangabeys
from SIVsmm infection in vivo
In humans, the CCR5D32 homozygous genotype provides
powerful protection against HIV-1 infection [39,40,42]. There-
fore, we asked if animals homozygous for CCR5-null alleles were
infected by SIVsmm. In order to more properly assess natural
an inverted white triangle. Transmembrane domains are indicated by shaded boxes and mis-sense amino acid sequences resulting from mutations
are highlighted.
doi:10.1371/journal.ppat.1001064.g001
Figure 2. Surface expression of wild-type and mutant CCR5 variants in vitro. 293T cells were transfected with expression plasmids encoding
smCCR5 wild-type (orange), smCCR5D2 (light blue), smCCR5D24 (magenta) and huCCR5-wt (green), along with empty expression plasmid (dark blue).
Untransfected 293T cells (shaded red) serve as controls. Cells were stained with an anti-CCR5 mAb (clone 3A9; APC-conjugated), which recognizes the
N-terminal region of both human and sooty mangabey CCR5 (right panel), or an isotype-matched control antibody (left panel).
doi:10.1371/journal.ppat.1001064.g002
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susceptibility, we restricted this analysis to YNPRC animals that
were naturally infected (n = 120) and those with documented SIV-
negative status (n = 72), and excluded animals in the colony known
to have been experimentally infected (n = 10).
As shown in Table 3, we found that among SM with the CCR5
homozygous wild-type genotype, 65% were naturally infected
while 35% were uninfected, and 62% of CCR5 heterozygous
animals were infected and 38% were uninfected. Unexpectedly,
among animals homozygous for CCR5-null alleles (n = 14), 50%
were naturally infected and 50% were seronegative. Thus, animals
lacking functional CCR5 genes are susceptible to natural SIVsmm
infection. The slightly lower prevalence of SIV infection among
animals in the CCR5-null group was not statistically significant
(p = ns; Chi-square test). We also compared the distribution of
genotypes within the SIV-negative and naturally-infected SIV
populations (Table 4). Similarly, there were no significant
differences in genotype distribution between the SIV serostatus
groups (p = ns for each genotype group; 2-sample proportions test),
although a slightly lower proportion of homozygous CCR5 mutant
animals was seen in the infected animals compared with SIV-
negative animals (5.8% vs. 9.7%; p= ns). Therefore, the CCR5-
null genotype does not prevent natural acquisition of SIVsmm
infection. Furthermore, neither heterozygosity nor homozygous
null genotype appears to significantly influence SM susceptibility
to SIVsmm infection in vivo, and while we cannot absolutely rule
out a small effect, any protection that might be afforded by CCR5-
null status would be slight. This result stands in marked contrast to
the profound protective effect of CCR5D32 homozygosity in
humans.
We also determined the genotypes of 10 animals at YNPRC
that were infected experimentally. Five of these animals were
homozygous for the CCR5 wild-type gene, three were heterozy-
gotes (all W/D2) and two were homozygous for smCCR5D2.
Furthermore, all but one of the TNPRC animals studied are
SIVsmm-infected, including a mix of both natural infections and
experimental inoculation done in earlier decades. Among the
infected animals were three homozygous CCR5-null animals,
while the one uninfected animal was heterozygous (W/D2).
Therefore, SM naturally deficient in CCR5 expression are
susceptible to experimental as well as natural SIVsmm infection,
confirming that non-CCR5 entry pathways can mediate SM
natural host infection.
Influence of smCCR5 genotype on plasma viral loads and
CD4 counts in SIVsmm-infected SM
We next asked if CCR5 genotype affected plasma viral loads in
infected animals. Based on previously collected data, the log10 viral
load (mean 6 SEM) was calculated for animals in each genotype
group; for animals with multiple data points available, their mean
viral load (log10) was used (Figure 4). This analysis showed robust
viral loads in all genotype groups, with a modest but statistically
significant gradient in VL dependent on the presence of a wild-
type CCR5 allele (p = 0.005 by Kruskal-Wallis test). Animals
possessing two wild-type alleles exhibited the highest viral load
(4.8360.10 log10), heterozygotes showed an intermediate level
(4.6560.10 log10), and infected animals with the CCR5-null
genotype had the lowest VL (4.3760.15 log10). Thus, there is
approximately 0.5 log10 difference in viral load in animals with
two wild-type compared with two CCR5-null alleles. The two
important points here are that homozygous mutant animals have
vigorous viral replication despite lacking functional CCR5, and
simultaneously exhibit a small but significant difference in plasma
viral load associated with increasing CCR5 gene dosage.
CD4 counts remain stable during chronic SIVsmm infection in
the vast majority of animals, but some exceptions have been noted
[46,47], so we next asked if SIV-infected animals exhibit
differences in CD4 counts depending on their CCR5 genotype.
However, there was no significant difference in CD4+ T cell levels
among the genotype groups, whether assessed based on absolute
counts (Figure S3A; p= ns, Kruskal-Wallis) or on the basis of CD4
percentage (Figure S3B; p = ns, ANOVA). These results suggest
that CD4+ T cell levels are maintained similarly in SIV-infected
SM regardless of CCR5 genotype.
smCCR5D2 does not support SIV entry in vitro
We then asked if there was any chance that the smCCR5D2
mutant allele, when expressed along with CD4, could support SIV
infection in vitro. We considered it unlikely but thought it was
necessary to test directly given the staining patterns by CCR5 mAb
Table 1. Genotypic frequencies in Sooty Mangabeys at
YNPRC.
Genotype: n
Observed
frequency (%)1
Predicted
frequency (%)2,3
W/W 102 50.5 50.8
W/D2 76 37.6 37.1
W/D24 8 4.0 3.9
D2/D2 13 6.4 6.8
D2/D24 3 1.5 1.4
D24/D24 0 0 0.1
Total 202
1Genotype distribution among all sooty mangabeys was determined by PCR
and direct genomic sequence analysis.
2Predicted genotype distribution was calculated by Punnett square analysis,
based on allelic frequencies (W= 0.71; D2= 0.26; D24 = 0.03) derived from
observed genotypes.
3Observed and predicted genotype frequencies are not significantly different
(Chi-square test).
doi:10.1371/journal.ppat.1001064.t001
Table 2. Observed and predicted genotype frequencies in
Sooty Mangabeys housed at the TNPRC1.
Genotype: n
Observed
frequency (%)2
Predicted
frequency (%)3,4
W/W 18 0.621 0.576
W/D25 7 0.241 0.288
W/D24 1 0.034 0.078
D2/D2 1 0.034 0.036
D2/D24 2 0.069 0.020
D24/D24 0 0.000 0.003
Total 29
1All animals except one are SIV-infected.
2Genotype distribution among all sooty mangabeys was determined by PCR
and direct genomic sequence analysis.
3Predicted genotype distribution was calculated by Punnett square analysis,
based on allelic frequencies (W= 0.76; D2= 0.19; D24 = 0.05) derived from
observed genotypes.
4Observed and predicted genotype frequencies are not significantly different
(Chi-square test).
5Includes one SIV-negative animal.
doi:10.1371/journal.ppat.1001064.t002
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3A9 in D2 homozygous primary mononuclear cells (Figure 3). We
also considered it important to test using SIVsmm from a CCR5D2
homozygous infected animal, in case viral adaptation might have
enabled use of an N-terminal region alone. Therefore, we generated
pseudotype virions carrying Env glycoproteins cloned directly from
plasma virus of an SIVsmm-infected CCR5D2 homozygous animal
(FNp), along with pseudotypes carrying Envs cloned from plasma of
an infected wild-type animal (FFv). Use of plasma virus ensured that
these Envs were derived from actively replicating virus. Target
293T cells were co-transfected with CD4 plus plasmids encoding
wild-type smCCR5, smCCR5D2, human CCR5 or an empty
vector as a control, then infected with the primary SIVsmm
pseudotypes. Of note, pseudotype virions carrying the FNp 5.1 Env
were considerably less infectious than the other Envs and very large
amounts of this virus were required to achieve equivalent infectious
inocula, which generally resulted in high levels of background for
this Env.
As shown in Figure 5, wild-type smCCR5 and human CCR5
support infection of all SIVsmm variants to similar levels. In
contrast, the smCCR5D2 allele does not support infection by any
of the viruses. Importantly, CCR5D2 does not function as a
coreceptor for Env variants from CCR5-null animals. Thus,
Figure 3. CCR5 surface expression on sooty mangabey CD4+ and CD8+ T cells ex vivo. (A) CCR5 staining on CD8+ T cells (left) and CD4+ T
cells (right) of uninfected sooty mangabeys was carried out between 2004 and 2009, and analyzed according to genotype groups (mean 6 SEM):
CCR5 wild-type (W/W; n= 38), heterozygous (W/D; n = 34) and homozygous mutant (D/D; n = 7). Because both D2 and D24 alleles are functionally null,
they were combined for this analysis. CCR5 expression by CD8+ T cells differs significantly between genotype groups (p,0.0001 by Kruskal-Wallis
test), while the trend for CD4+ T cells does not reach statistical significance (p =ns). (B) FACS plots showing CCR5 staining on CD4+ and CD8+ T cells
from representative homozygous wild-type, heterozygous and homozygous mutant animals.
doi:10.1371/journal.ppat.1001064.g003
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SIVsmm infections in CCR5-null animals are mediated through
pathways independent of CCR5.
Use of alternative coreceptors by SIVsmm isolates
The data presented here indicates that SIVsmm must be able to
use entry pathways other than CCR5 for replication in vivo. It is
long known that many SIV strains use a number of alternative
coreceptors in addition to CCR5 in vitro, although these viruses
rarely use CXCR4. We therefore tested the ability of SIVsmm
envelopes to mediate infection through human CCR2b, CCR3,
CCR8, GPR1, GPR15 (BOB), CXCR6 and CXCR4. This
analysis employed the uncultured SIVsmm envelope glycoproteins
cloned from plasma of the CCR5-null (FNp) and homozygous
wild-type (FFv) infected animals.
As shown in Figure 6, all SIVsmm envelope glycoproteins tested
mediated entry into cells expressing CD4 in conjunction with
GPR15 and CXCR6, while GPR1 was also used but less efficiently.
In contrast, none of the SIVsmm envelope glycoproteins could use
CXCR4 as a coreceptor, nor CCR3 or CCR8 (data not shown).
Interestingly, SIVsmm envelope glycoproteins failed to use CCR2b,
an entry pathway employed by SIVrcm in RCM that typically lack
CCR5 due to a high prevalence of the D24 mutation [43].
Furthermore, the patterns of alternative coreceptor use were similar
for envelope glycoproteins derived from CCR5-null and CCR5
wild-type animals, indicating that alternative coreceptor utilization
is a feature shared by SIVsmm regardless of whether the host animal
expresses CCR5. While absolute luciferase production varied
among experiments, GPR15 and CXCR6 typically supported
levels of infection similar to that mediated by CCR5 (Figure S4),
although transfected targets likely represent maximum levels of
potential utilization relative to primary cells that would express these
molecules at physiological levels.
SIVsmm infects sooty mangabey CCR5-null primary
PBMC in vitro and infection of wild-type PBMC is not
blocked by the CCR5 antagonist maraviroc
We next investigated the role of non-CCR5 pathways in
SIVsmm infection of primary SM cells, utilizing both the specific
CCR5 antagonist maraviroc and CCR5-null PBMC derived from
CCR5D2 homozygous animals. Maraviroc blocks chemokine
signaling and HIV-1 Env entry through human and rhesus
macaque CCR5 [48,49], but blocking of SM CCR5 coreceptor
function has not been reported. Therefore, we first tested the effect
of maraviroc on SIVsmm entry through smCCR5 in transfected
cells. As shown in Figure 7A, maraviroc blocked SIVsmm
pseudotype infection of target cells expressing CD4 and smCCR5,
reducing luciferase expression to the level seen with target cells
expressing CD4 alone (data not shown), indicating complete
blocking of smCCR5-mediated entry by maraviroc. In contrast,
maraviroc did not inhibit SIVsmm entry mediated by GPR15
(Figure 7A), nor did it affect entry by VSV-G pseudotypes (data
not shown), confirming that blocking is not a nonspecific effect.
Table 3. Prevalence of naturally-acquired SIV infection
among YNPRC sooty mangabeys based on CCR5 genotype.
Genotype1 SIV positive2 (n) SIV negative3 (n) % SIV infected4
W/W 63 34 65
W/D 50 31 62
D/D 7 7 50
Total 120 72 63
1CCR5D2 and D24 alleles were grouped together as defective for expression (D).
2Includes animals known to be infected naturally in the wild or in captivity, and
excludes 10 animals infected experimentally.
3Includes animals known to be SIV-negative at the time of last survey.
4SIV prevalence does not differ significantly among the genotype groups (Chi-
square test).
doi:10.1371/journal.ppat.1001064.t003
Table 4. Genotypic distribution among YNPRC sooty
mangabeys based on SIV infection status.
Genotype1 SIV positive SM (n=120)2,4 SIV negative SM (n=72)3,4
W/W 0.525 0.472
W/D 0.417 0.431
D/D 0.058 0.097
1CCR5D2 and D24 alleles were grouped together as defective for expression (D).
2Includes animals known to be infected naturally in the wild or in captivity, and
excludes 10 animals infected experimentally.
3Includes animals known to be SIV-negative at the time of last survey.
4Differences in genotype distribution among animals based on SIV infection
status are not statistically significant (2-sample proportions test).
doi:10.1371/journal.ppat.1001064.t004
Figure 4. SIV plasma viral load measurements in infected sooty
mangabeys between genotype groups. Plasma viral load mea-
surements (VL log10; means 6 SEM) collected in surveys carried out
between 2004 and 2009 of infected animals in the wild-type (n = 60),
heterozygous (n = 49), and homozygous mutant (n = 7) genotype
groups. The D2 and D24 alleles were combined for this analysis. The
difference in VL between homozygous wild-type and CCR5-null
genotype groups (W/W vs. D/D) is statistically significant (p,0.05;
Dunn’s multiple comparison test) whereas the differences for the
heterozygous group (W/D vs. W/W; W/D vs. D/D) does not reach
statistical significance (p =ns; Dunn’s multiple comparison test).
doi:10.1371/journal.ppat.1001064.g004
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Next we asked if maraviroc would affect productive infection of
SM primary PBMC by infectious isolates of SIVsmm. PBMC from
an uninfected CCR5 wild-type (FAk) and a CCR5-null (FAz)
animals were activated with PHA for three days, and then infected
in the presence and absence of maraviroc with two SIVsmm
primary isolates (M923 and M951), which were both derived from
CCR5 wild-type infected animals. Viral replication was measured
as SIV gag p27 levels in supernatants collected periodically post-
infection (Figure 7B).
We first noted that both SIVsmm isolates were able to
productively infect primary PBMC in vitro from the CCR5-null
SM (FAz). In these cells, there was no difference in replication
associated with CCR5 blocking by maraviroc, as expected given the
lack of functional CCR5 encoded by the mutant genes. This result
indicates that SIVsmm infection of CCR5-null PBMC can occur
independently of CCR5. We then tested CCR5 wild-type PBMC
(FAk), and found that SIVsmm established productive infection in
both the absence and presence of maraviroc. Furthermore, there
was no difference in the level of infection achieved when CCR5 was
blocked, based on p27 antigen production. This finding indicates
that SIVsmm efficiently enters even CCR5-expressing SM primary
PBMC through pathways independent of CCR5.
CCR5 genotypes in sooty mangabeys with SIV evolution
to X4 coreceptor use
Unlike HIV-1 in humans, CXCR4 use by SIV in SM is rare.
However, a few exceptions have been noted in which CXCR4 use
emerged following experimental infection, which was associated
with profound CD4+ T cell loss although not clinical AIDS [47].
Therefore, to ask if restricted CCR5+ target cell availability due to
genetic absence of the coreceptor might be linked to CXCR4
emergence, we genotyped two infected CD4-low SM previously
described in which CXCR4-using SIVsmm variants emerged [47].
Neither animal possessed a CCR5-null genotype: one was CCR5
homozygous wild type and the other was heterozygous for the
CCR5D2 allele. Thus, the fact that acquisition of CXCR4 use by
SIVsmm can occur but is not associated with animals that
genetically lack CCR5 is consistent with the notion that alternative
pathway-supported entry in vivo is robust and lack of CCR5 does
not serve as a driving force in the rare cases with emergence of
CXCR4 use.
Discussion
We unexpectedly found that 8% of sooty mangabeys in a large
US captive population lack functional CCR5 due to the high
prevalence (29%) of mutations in the CCR5 gene that abrogate cell
surface expression and SIV coreceptor function. Despite their
CCR5-null status, homozygous mutant animals are susceptible to
natural as well as experimental SIVsmm infection and display viral
loads only modestly lower than CCR5 wild-type animals. In vitro,
SIVsmm enters primary SM lymphocytes independently of CCR5,
and Envs from both wild type and CCR5-null infected animals use
several alternative coreceptors in addition to CCR5, but do not use
CXCR4. These data indicate that both CCR5 and alternative
coreceptor pathways mediate cell entry and robust viral replication
in vivo. The recognition that both CCR5-dependent and indepen-
dent pathways are used in the SM natural host has significant
implications for understanding viral tropism in vivo and CD4+ T cell
subset targeting that may regulate the outcome of natural host
infection, and raises important questions about entry coreceptor use
in pathogenic non-human primate models of AIDS. This finding
also explains the previously obscure reason for widespread and
efficient use of alternative coreceptors among the SIVmac/smm
family of viruses. Finally, it provides a third example of convergent
evolution resulting in disruption of CCR5 function among primates,
with consequences for virus-host interactions in SM that differ from
both humans homozygous for CCR5D32 and red capped
mangabeys homozygous for CCR5D24.
From the original descriptions of alternative coreceptor use by
SIVmac/smm viruses, and subsequently by other SIV strains, the
reason for conserved use of these pathways has remained elusive
Figure 5. Mutant smCCR5D2 does not support SIV infection in vitro. 293T cells were transfected with CD4 alone (yellow bars) or in
combination with wild-type smCCR5 (blue bars), smCCR5D2 (green bars) or wild-type human CCR5 (red bars). Target cells were infected with
luciferase-expressing pseudotype virions carrying Env glycoproteins that were cloned from plasma of two SIVsmm-infected sooty mangabeys (FFv:
W/W SM; FNp: D2/D2 SM). Pseudotypes carrying the R5-tropic HIV-1 Env JRFL and virions lacking envelope glycoproteins served as controls. Infection
was measured by relative light units (RLU) in cell lysates 3 days after infection (mean 6 SD).
doi:10.1371/journal.ppat.1001064.g005
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[20,21,50]. It has been repeatedly shown that various SIV isolates
can infect primary human D32 homozygous PBMC independent
of both CCR5 and CXCR4, indicating that alternative corecep-
tors are expressed in a manner that supports infection in primary
lymphocytes ex vivo, at least in cells of human origin
[51,52,53,54,55,56]. Our data show for the first time that the
alternative coreceptors are used by SIVsmm in primary simian T
cells ex vivo and, more importantly, in vivo in the natural host from
which the SIVmac/smm family derived. Several important
questions are raised by this finding: (1) are alternative pathways
also operative in SM with wild-type CCR5 expression, or are they
only relevant if CCR5 is absent; (2) what essential role or selective
advantage do they provide SIVsmm in SM infection in vivo that has
led to conservation of alternative coreceptor entry pathway use; (3)
does alternative coreceptor use define a novel population of
CCR5-negative target cells that contributes to the ability of host
and virus to coexist without disease, and; (4) what role do
alternative pathways play in infection of macaques, the nonhuman
primate model used to study AIDS.
Prior to this confirmation that alternative pathways are used in
vivo, it seemed plausible that alternative coreceptor use by
SIVsmm/mac was an in vitro epiphenomenon of little biological
significance. Recognizing that they are operative in vivo, it seems
more likely that conservation of their use among SIV isolates
Figure 6. Alternative coreceptor utilization by SIVsmm Envs in vitro. 293T cells were transfected with CD4 alone or in combination with (A)
the alternative coreceptors GPR1, GPR15 and CXCR6, or (B) CXCR4, CCR2b or CCR5. Target cells were then infected with luciferase-expressing
pseudotype virions containing SIVsmm Envs from infected CCR5 wild-type (FFv: W/W SM) and CCR5-null (FNp: D2/D2 SM) animals. Envs from
SIVmac239, HIV-1 JRFL and virions lacking Env served as controls. Infection was assayed by RLU (mean 6 SD) measured 3 days after infection.
doi:10.1371/journal.ppat.1001064.g006
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reflects some role that, if not completely essential, offers a selective
advantage for the virus. Comparison of viral load data among the
genotype groups showed robust replication in the absence of
CCR5, but a step-wise increase associated with the presence of one
or two functional CCR5 alleles, and ex vivo blocking studies with
maraviroc confirmed that both wild-type and CCR5-null primary
PBMC possess efficient CCR5-independent entry pathways. On
one hand, if the relevant coreceptor(s) are expressed only on cells
that also express CCR5, the use of multiple pathways in vivo might
be an example of functional redundancy acquired by SIV,
reminiscent in part of the functional redundancy of the
chemokine/chemokine receptor system. On the other hand, if
CCR5 and alternative pathways are expressed on distinct or only
partially overlapping CD4+ T cell subsets, the 0.5 log10 VL
difference between D/D and W/W animals may also be consistent
with separate components of plasma viremia supported by CCR5
and non-CCR5 pathways (and an intermediate gene-dosage effect
in the presence of one CCR5 allele). It is notable that the degree of
depletion in SM gut CD4+ T cells exceeds the proportion that
express detectable CCR5 [24], and it will be important to
determine if this is due to infection and targeting of CCR5-
negative cells in wild-type animals mediated by other coreceptors.
As to why alternative coreceptor use is conserved among
SIVsmm and related strains, it seems unlikely to result from the
Figure 7. Effect of CCR5 blocking on SIVsmm use of CCR5 and entry into primary SM PBMC. (A) 293T cells were transfected with CD4 in
combination with wild-type smCCR5 or GPR15. Two days post-transfection, target cells were pretreated for one hour with or without the CCR5
antagonist, maraviroc (15uM), and then infected with pseudotype virions carrying SIVsmm Envs from a CCR5 wild-type animal (FFv) and a CCR5-null
animal (FNp). Three days later, infection was measured based on RLU (mean 6 SD) in cell lysates. (B) Growth curves from infection of primary SM
PBMC (FAk: W/W SM; FAz: D2/D2 SM). Cells were stimulated for 3 days with PHA, then pretreated for one hour with or without maraviroc (15 uM),
followed by infection with two different SIVsmm primary isolates (M923 and M951) in the continued presence or absence of maraviroc. SIV Gag p27
antigen levels in viral supernatants were measured by ELISA.
doi:10.1371/journal.ppat.1001064.g007
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8% prevalence of CCR5-null animals in SM, and more likely
reflects a unique role that provides an advantage over CCR5 alone
in transmission, establishment of reservoirs or other aspects of
infection. Sooty mangabeys overall express very low levels of
CCR5 on CD4+ T cells, which has been proposed as an
evolutionary adaptive response to ‘‘protect’’ critical target cells and
minimize pathogenesis [17,18]. If so, acquisition of alternative
coreceptor use by the virus may have reflected a ‘‘counter-
measure’’ to maximize replication capacity, although doing so in a
manner that still retains the nonpathogenic nature of infection.
Thus, the use of alternative entry pathways in vivo might enable
infection of a novel CCR5-negative target cell population that is
more expendable than CCR5+ cells, allowing the virus to replicate
efficiently without causing disease in the face of extremely
restricted CCR5 expression. It will therefore be important to
define the distribution of cells infected in animals with and without
functional CCR5.
An important question raised by these SM findings is whether
alternative coreceptors are utilized in pathogenic infection of
macaques, which is widely used to model human AIDS. While
CCR5 clearly plays a principal role as evidenced by substantial
albeit variable viral suppression by CCR5 antagonists [57,58], levels
of CD4+ T cell infection in rhesus macaques can also substantially
exceed the proportion of cells that express detectable CCR5 [23].
While it is possible that infection of apparently CCR5-negative
targets reflects entry mediated by CCR5 at levels below the
threshold detectable by FACS, our findings revive the question of
whether it may be mediated by additional entry pathways. Few
studies have attempted to address alternative coreceptor use in vivo.
One report showed that mutations that abrogated GPR15 use by
SIVmac had little effect on replication or pathogenesis in rhesus
macaques [22]. Similarly, when pigtail macaques (Macaca nemestrina)
were infected with SIVmne (also derived from SIVsmm), serial
isolates exhibited decreasing ability to use alternative entry
pathways when assayed in vitro [51]. On the other hand, in
cynomolgus macaques (Macaca fascicularis) infected with SIVsmm,
animals with progressive disease showed retention or broadening of
alternative coreceptor use while those without disease progression
showed narrowing of alternative coreceptor use [52]. Thus, it
remains to be determined whether alternative pathways support
entry in particular subsets of CD4+ T cells in the macaque model in
vivo. Of note, emergence of CXCR4 use is common in HIV-1
infection of humans but exceedingly infrequent in macaques
infected with SIVmac. HIV-1 rarely uses alternative coreceptors
efficiently and evolution to CXCR4 use by HIV-1 is believed to
result, in part, from loss of CCR5+ target cells in late stage disease.
Thus, the availability of efficient alternative entry pathways may be
one reason that SIV rarely evolves to use CXCR4.
The SIVsmm Envs examined here use GPR15 and CXCR6 for
entry quite efficiently in vitro, and use GPR1 somewhat less
efficiently. This result is concordant with coreceptor use patterns
of multiple other SIV isolates [22,23,30]. In human blood cells,
CXCR6 is highly expressed on CD4+ and CD8+ memory but not
naı¨ve T cells, and on gamma-delta T and to a lesser extent NK
cells [59], although others have reported expression by CD4+
naı¨ve T cells as well [60]. Interestingly, CXCR6 expression is
regulated by T cell activation in a pattern that is tightly linked with
CCR5 expression in response to some stimuli, but markedly
different in response to others [59]. GPR15 is also expressed on
lymphoid and myeloid cells but with less information about
specific distribution patterns [20,21,61]. Of note, both CXCR6
and GPR15 are also highly expressed in intestinal tissues [20,62],
raising the question of whether alternative coreceptor use may be
involved in mucosal events that play a central role in infection.
Thus, CXCR6 and GPR15 are particularly likely candidates for
mediating SM infection independent of CCR5, and further studies
are required to determine which one or ones are responsible for
entry into primary SM PBMC ex vivo and infection in vivo.
One of the most important priorities in HIV/AIDS research at
present is understanding why infected natural hosts remain healthy
while rhesus macaques infected with SIV, humans infected with
HIV-1 or HIV-2, and chimpanzees infected with SIVcpz develop
AIDS. Many features are shared by non-pathogenic natural host
and pathogenic non-natural host infection including sustained
high level viremia, vigorous immune activation during acute
infection, and extensive depletion of gut mucosal CD4+ T cells. In
pathogenic infections it is believed that in addition to infection and
loss of short-lived T effector and T effector memory cells, damage
to long-lived CD4+ Tcm populations that impairs the capacity to
maintain immune cell homeostasis is a critical factor in progressive
immunodeficiency [26,27,63]. CCR5 levels are profoundly lower
on SM CD4+ T cells compared with RM and humans, which may
restrict the target cells available for infection in vivo [17,18]. More
recent findings indicate that CD4+ Tcm in SM have particularly
impaired CCR5 expression upon activation, and this corresponds
with markedly lower levels of cell-associated infection in Tcm
compared with Tem cells in SM, whereas both populations are
similarly infected in RM (G.S. and M.P; unpublished observa-
tions). Thus, in addition to the role of CCR5, it will be important
to define the distribution and use of other coreceptors by SIVsmm
in its natural host as well as in pathogenic rhesus macaque
infection. Another prominent difference between pathogenic
infection and nonpathogenic natural host infection is the presence
of sustained high level generalized immune activation in rhesus
and humans, whereas acute infection in natural hosts is associated
with transient immune activation that rapidly resolves
[11,29,35,64,65,66]. Sustained immune activation during chronic
infection may be an additional factor driving T cell turnover and
depletion. A principal mechanism driving chronic immune
activation is believed to be translocation of microbial products
due to disruption of gut mucosal barrier integrity that occurs early
in infection [31]. However, gut mucosal lymphocyte infection and
CD4+ T cell depletion occurs in natural host as well as pathogenic
host infection [24,33]. One potentially critical difference is the loss
in human and rhesus macaque infection, but preservation in
natural hosts, of mucosal CD4 Th17 cells, which play a critical
role in gut mucosal immune defense [35,36,37,38]. Why gut Th17
CD4+ T cells are preserved in infected natural hosts but depleted
in other hosts remains to be determined, but the critical role of
entry coreceptors in determining tropism and cell subset infection
in vivo suggest that both CCR5 and alternative coreceptor
pathways must be defined in order to understand the targeting
versus protection of critical CD4+ cell subsets.
In addition to the YNPRC and TNPRC SM colonies, we also
found the D2 allele in SM in the Tai forest of Cote d’Ivoire,
confirming its presence not just in captive but also in wild-living
West African animals, albeit at a lower frequency. Sooty
mangabeys at YNPRC were derived from multiple sources and
their history is not well documented [67], so it is difficult to know
for sure from what geographic regions in West Africa these
animals descended. Of note, the D2 allele was not described in
earlier studies that reported the D24 allele in SM from West Africa
and the YNPRC colony [43,44]. However, CCR5 alleles in those
studies were screened by PCR amplicon size, which could
discriminate a 24 bp size difference but is unlikely to distinguish
a 2 bp difference between the wild type and D2 alleles.
The identification here of SM CCR5D2 brings to three the
number of primates known to have a high prevalence of defective
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CCR5 alleles. Interestingly, each of the three examples of
populations with homozygous mutant CCR5 individuals shows
distinct patterns of host/virus interactions. For HIV-1 in humans,
which have the lowest prevalence of defective CCR5 genes (,1%
among Caucasians), CCR5 use is a stringent requirement for
establishment of new infections, and its absence in the host
provides almost complete protection from infection even though
late-stage variants can use CXCR4 and, occasionally, other
coreceptors. In RCM, which have the highest prevalence of
CCR5-null individuals ($70%), SIVrcm has adapted to use
CCR2b as a coreceptor and lost the ability to use CCR5 [43].
SIVsmm infection in SM, which have an intermediate prevalence
of CCR5-null individuals (8% in this population), demonstrate an
intermediate relationship, in which alternative coreceptors effi-
ciently mediate both natural and experimental infection in the
absence of CCR5, but CCR5 use by the virus is retained, perhaps
because both CCR5 and alternative pathways together maximize
replication in the majority of animals, while the non-CCR5
pathways are required in the CCR5-null animals.
It is somewhat unexpected that SIVsmm does not use CCR2b,
which is the route of entry taken by SIVrcm in the absence of
CCR5. SM and RCM are closely related and sometimes
considered sub-species within the same species [43,68]. The
presence of the same CCR5D24 allele in RCM and SM has been
interpreted as indicating an origin prior to separation of these
populations, although it is uncertain if the remarkably high
frequency CCR5D24 in the RCM population reflects selective
pressure exerted by an environmental or infectious cause, or
founder effect [43]. Another question raised by our results is
whether the SM CCR5D2 and the SM/RCM CCR5D24 emerged
independently, resulting in deletions in the same region due to
multiple nucleotide repeats enabling recombination, or given the
overlapping sites whether D2 emerged first and additional events
led to D24. Since D2 is not expressed, it is unlikely that further
deletions would lead to any additional selective advantage, and
two separate recombination deletion events in the same region of
the same gene seem more probable.
What selective pressures might have led to three independent
primate CCR5 deletion alleles is uncertain. CCR5D32 has been
present in the human population for at least 3000 years [69], far
longer than HIV-1, and despite considerable speculation on
infectious or other pressures, both what factors fueled its
emergence and when it occurred remain enigmatic [70]. In
contrast, SIV has been endemic in the SM and RCM populations
for much longer, although whether its entry predated separation of
the populations is uncertain [68]. The CCR5 mutation is currently
not essential for protection from SIV-induced pathogenesis, but it
is plausible that each of the mutations result from ancestral
evolutionary pressure by pathogenic SIV infection. For SM,
genetic abrogation of CCR5 expression may have been an
additional, complementary response to control pathogenesis along
with phenotypic CCR5 downregulation [18]. If so, in both SM
and RCM the virus then acquired mechanisms to circumvent the
restriction, by expanding coreceptor use for SIVsmm or switching
for SIVrcm, yet the hosts then acquired other additional
mechanisms to avoid pathogenesis. Alternatively, it may be that
all three CCR5 mutations, human, SM and RCM, reflect
evolutionary adaptation to some other as-yet unidentified
infectious or other environmental factor acting similarly on all
three types of primates. Nevertheless, whatever its origin and
frequency, the SM CCR5D2 mutation here expands the pathways
known to support infection in this important natural host model,
the identity, distribution and utilization of which must be taken
into account in understanding SM infection in vivo, and the
similarities or differences from RM infection that determine
outcome from infection.
Materials and Methods
Ethics statement
All animal experimentation was conducted following guidelines
established by the Animal Welfare Act and the NIH for housing
and care of laboratory animals and performed in accordance with
Institutional regulations after review and approval by the Insti-
tutional Animal Care and Use Committees (IACUC) at the Yerkes
National Primate Research Center (YNPRC) or the Tulane
National Primate Research Center (TNPRC). Studies were also
reviewed and approved by the University of Pennsylvania
IACUC.
Animals and primary cells
These studies utilized blood cells from animals housed at the
YNPRC or TNPRC. Peripheral blood mononuclear cells (PBMC)
were isolated from whole blood using standard density gradient
separation methods. For genomic analysis, approximately 0.86106
PBMC were lysed in DNA lysis buffer (100 mM KCl; 0.1% NP40;
20 mM Tris pH 8.4; 0.5 mg/ml proteinase K; 200ul total volume)
and used as a template for PCR amplification. For infection
studies, cryopreserved PBMC were thawed under standard
conditions and maintained at 106 cells/ml in RPMI supplemented
with 10% FBS, 1% glutamine and 1% penicillin-streptomycin,
stimulated for 3 days with 5 mg/ml of phytohemagglutinin (PHA;
MP Biomedical), infected and then maintained in the same media
in the presence of IL-2 (50 U/ml; Novartis). Analysis of wild SM
genotypes was carried out on purified DNA derived from fecal
specimens collected in Cote d’Ivoire, which were previously
characterized by mitochondrial DNA sequence analysis to
represent 33 distinct individuals [45].
Cloning SM CCR5 genes
Full-length SM-CCR5 genes were amplified by PCR from SM
genomic DNA using high fidelity DNA polymerase (Phusion;
Finnzymes) and primers based on conserved 59 and 39 regions of
published SM CCR5 coding sequences (forward: 59-ATG GAC
TAT CAA GTG TCA AGT CCA ACC-39; reverse: 59-TCA
CAA GCC AAC AGA TAT TTC CTG CTC C-39). PCR
reactions contained Phusion polymerase (1 unit) in HF buffer,
primers (0.5 uM), dNTPs (0.2 mM) and 200 ng of purified
genomic DNA as template in a 50 ul reaction volume. Thermo-
cycling conditions: initial denaturation at 98uC for 45 seconds,
followed by 20 cycles of 98uC for 10 seconds, 71uC for 30 seconds
and 72uC for 90 seconds, with a final extension step of 72uC for
10 minutes. PCR amplicons were column purified (QIAquick
PCR Purification kit; Qiagen) and then used in a second PCR
reaction employing primers that incorporated a HindIII restriction
site at the 59 end of the coding region and a BamHI restriction site
at the 39 end of the CCR5 coding sequence (forward: 59-GCT
GCT ATA AGC TTC CAC CAT GGA CTA TCA AG-39;
reverse: 59-AGC GAG CGG ATC CTC ACA AGC CAA CAG
ATA-39; restriction sites underlined). Thermocycling conditions
for the second PCR reaction were: an initial denaturation step at
98uC for 45 seconds, followed by 5 cycles of 98uC for 10 seconds,
71uC for 45 seconds and 72uC for 60 seconds, followed by 15
cycles of 98uC for 10 seconds, 76uC for 45 seconds and 72uC for
60 seconds, and final extension at 72uC for 10 minutes. CCR5
amplicons were cloned into the expression plasmid pcDNA3.1+
(Invitrogen) using HindIII and BamHI, and screened by restriction
analysis followed by sequence confirmation. Sequences of the
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smCCR5D2, smCCR5D24 and smCCR5 wild-type genes cloned
here have been deposited in Genbank (accession numbers
HM246694, HM246695 and HM246693, respectively).
CCR5 genotyping of SM
A two-step PCR-based genotyping assay was developed that
identifies CCR5 wild-type and CCR5D2 alleles based on
differential primer annealing, using genomic DNA from lysates
of SM PBMC. Genomic DNA was subject to PCR amplification
using the first round primers described above, to amplify the entire
CCR5 coding region, in reactions that contained Platinum Taq
polymerase (1 unit; Invitrogen), 1.5 mM MgCl2, primers (0.5 uM
each), dNTPs (0.2 mM), 1–3 ul DNA lysate and Taq buffer in
25 ul reaction volumes. Thermocycling conditions were: initial
denaturation at 98uC for 45 second followed by 10 cycles of 94uC
for 20 seconds, 68uC for 45 seconds, 72uC for 60 seconds and
final extension at 72uC for 10 minutes. The product of this
reaction (2.5 ul) was then used as a template for two separate
second-round amplifications, each of which used a common
downstream primer but different upstream primers specific for the
wild-type and D2 alleles, respectively (forward CCR5 wild-type:
59-ATC ACT TGG GTG GTG GCT-39; forward CCR5D2: 59-
ATC ACT TGG GTG GTG CGT-39; common downstream: 59-
GGT GTT CAG GAG AAG GAC AAT GTT G-39). The second
round PCR reaction used the same conditions as the first reaction.
Products of the wild-type and D2 amplification reactions were
visualized by 2% agarose gel electrophoresis and ethidium
bromide staining, which demonstrated a 325 base pair product
following amplification with wild-type or D2 primer pairs, or both
for heterozygotes (Figure S1A).
Each animal was also screened for the CCR5D24 deletion allele
with a two-step PCR-based assay. Products of the first round PCR
reaction described above, were subjected to nested amplification
with inner primers (forward: 59-GGC TAT CGT CCA TGC
TGT GT-39; reverse: 59-GAC CAG CCC CAA GAT GAC TA-
39) and thermocycling conditions as follows: initial denaturation at
94uC for 45 seconds, followed by 25 cycles of 94uC for 20 seconds,
59uC for 45 seconds, 72uC for 60 second, and a final extension at
72uC for 10 minutes. Products were visualized by 3% agarose gel
electrophoresis and ethidium bromide staining, yielding a 205 base
pair product from the D24 allele, which was easily distinguishable
from the 227–229 bp product from the wild-type and CCR5 D2
alleles (Figure S1B).
As a secondary confirmation of genotypes established by PCR
screening, direct bulk sequencing was carried out on PCR
amplified genomic DNA. Amplification was done using the outer
primer set as described above, except that Phusion high fidelity
polymerase was used for 30 cycles. Products were column-purified
and sequenced. Genotypes were verified by manual inspection to
confirm the presence of uniform sequences for homozygous
animals, or detection of expected frameshifts resulting in
overlapping sequences for heterozygous animals (Figure S1C).
For fecal-derived samples, 0.5 ug of purified DNA (of which
only a fraction reflected host-derived DNA) was PCR amplified for
35 cycles using first round outer primers as described above, and
then subjected to nested amplification for 30 cycles using the inner
primer set described above. Products were then subjected to direct
sequence analysis.
Pseudotype luciferase reporter virus infections and
coreceptor use analysis
SIVsmm Env-mediated entry was analyzed using luciferase-
expressing reporter viruses pseudotyped with envelope glycoproteins
of interest. Pseudotype viruses were generated by co-transfecting
293T cells with a plasmid encoding the NL4-3-based env-deleted
luciferase-expressing virus backbone (pNL-luc-E2R+) [71] along
with expression plasmids encoding SIVsmm, SIVmac, HIV-1 or
VSV-g envelope glycoproteins. Cells were transfected overnight
using Fugene (Roche) and washed the next day to remove residual
transfection reagent. Supernatants were collected 2 days later,
clarified by centrifugation and stored at280uC until use. Pseudotype
viruses were quantified based on HIV-1 Gag p24 antigen ELISA
(PerkinElmer) and virion infectivity measured on U87 cells stably
expressing CD4 and CCR5. Inocula were then standardized on the
basis of infectivity in U87/CD4/CCR5 cells (16106 relative light
units; RLU).
The ability of pseudotype viruses to use different coreceptors
was assayed in target 293T cells expressing CD4 and the
coreceptor of interest. Target cells were prepared by co-
transfection with expression plasmids carrying CD4 and the
desired co-receptor (1ug of each plasmid) using Fugene. Cells were
re-plated one day post-transfection at 26104 cells/well in 96-well
plates and then infected the following day with pseudotype
reporter viruses using equivalent inocula (16106 RLU) by spin
inoculation for 2 hours at 1200G. Three days later cells were lysed
(0.5% Triton X-100 in PBS) and infection quantified on the basis
of luciferase production in target cells, determined by adding an
equal volume of luciferase substrate (Promega) and measuring
luciferase activity in RLU with a luminometer.
SIV envelope clones and infectious viruses
SIV envelopes used in pseudotype infections were generated
from plasma of SIVsmm-infected CCR5 wild-type (FFv) and D2
homozygous (FNp) SM by single genome amplification (SGA)
using methods and protocols previously described and cloned into
pcDNA3.1 using Topo TA (Invitrogen) [72,73]. Infectious
SIVsmm strains M923 and M951 were isolated as previously
described [74] and stocks were prepared in primary SM PBMC.
FACS analysis of wild-type and mutant CCR5 surface
expression
293T cells were transfected with wild-type or mutant forms of
CCR5 using Fugene according to manufacturer’s instructions.
One day later cells were detached by incubation in PBS containing
2 mM EDTA, washed in FACS buffer (PBS containing 1% FBS
and 0.1% sodium azide), and stained with the CCR5 monoclonal
antibody, clone 3A9-[APC] (BD Pharmingen) or isotype-matched
control. Cells were analyzed using a FACS Caliber flow cytometer
(BD Biosciences) and FloJo software (Tree Star, Inc.) to determine
CCR5 surface expression.
SIV infections of primary SM PBMC
PHA-stimulated SM PBMC were plated in 96-well plates at
2.56105 cells/well, incubated for 1 hour in the presence or
absence of the CCR5 antagonist maraviroc (15 uM; Pfizer), and
then infected with SIVsmm strains (M923 and M951) by spin
inoculation (12006g for 2 hours) followed by overnight incuba-
tion. The next day cells were washed in PBS and maintained in
media containing IL-2 (50 U/ml), with or without maraviroc
(15 uM). Cell supernatants were collected periodically for 3 weeks
and replication measured by SIV Gag p27 antigen in cell
supernatant by ELISA (Advanced BioScience Laboratories).
Analysis of SM virological and immunological parameters
Clinical data on infected and uninfected SM housed at YNPRC
has been reported previously for surveys carried out in 2004–5 and
2006–7 and 2008–9 [75]. CD3, CD4 and CCR5 expression on
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PBMC were analyzed by FACS and plasma viral loads were
measured by real-time PCR as described [11,75]. For purposes of
analysis, any undetectable viral loads were set at 75 copies, the
lower limit of detection. In cases where animals seroconverted
during the period of observation, data from prior to infection was
included with uninfected animals, while data from after infection
was included with infected animals. If multiple measurements were
available for individual animals for any parameters, mean values
were utilized.
Statistical analysis
Virological and immunological data were compared between
genotype groups using ANOVA or Kruskal-Wallis test followed by
the Dunn’s multiple comparison test for multiple groups. The two-
sample proportions test and Chi-Square test were used for
comparison between independent groups. Statistical tests were
performed using Prism 4.0 software and OpenEpi: Open Source
Epidemiologic Statistics for Public Health, Version 2.3. Data were
considered significant when P-value was below 0.05.
Supporting Information
Figure S1 Analysis of sooty mangabey CCR5 genotypes. (A)
Genomic DNA was analyzed by PCR in two separate reactions
that contained primers specific for the wild-type or D2 CCR5
alleles. (B) Genomic DNA was amplified with CCR5-specific
primers that generate an amplicon of 227–229 bp for the D2 and
wild-type alleles, or 205 bp for the D24 allele. Note that animals
1–6 in panel A do not correspond to numbers in panel B. (C)
Direct sequence validation of genotypes is shown in representative
chromatographs of animals from each of the 5 genotypes identified
in this analysis: W/W, W/D2; D2/D2; W/D24 and D2/D24. Red
arrow indicates the site of D2 or D24 frameshifts and blue arrow
indicates a single nucleotide polymorphism (T in wild-type; G in
D2 and D24 alleles) that results in a coding change (Leu in wild-
type; Val in D2 and D24 alleles).
Found at: doi:10.1371/journal.ppat.1001064.s001 (0.81 MB TIF)
Figure S2 Lack of dominant negative effect of mutant CCR5
alleles. 293T cells were transfected with wild-type smCCR5
plasmid (1 ug) along with plasmids encoding CCR5D2, CCR5D24
or pcDNA3 (1 ug of each plasmid). CCR5 expression was
determined by staining with mAb 3A9 and FACS analysis.
Found at: doi:10.1371/journal.ppat.1001064.s002 (0.27 MB
TIF)
Figure S3 Blood CD4+ T cell levels in infected sooty mangabeys
between genotype groups. (A) CD4+ T cell counts (cells/ul; mean
6 SEM; left) and (B) CD4+ T cell as a percentage of CD3+ cells
(mean 6 SEM; right) from infected animals in the wild-type
(n = 60), heterozygote (n = 49) and homozygous mutant (n = 7)
genotype groups. CD4+ T cells are not significantly different
between groups (p = ns for absolute cell counts by Kruskal-Wallis
test; p = ns for %CD4+ cells by ANOVA).
Found at: doi:10.1371/journal.ppat.1001064.s003 (0.27 MB TIF)
Figure S4 Relative use of alternative coreceptors compared with
CCR5. Representative experiment in which CCR5 and alterna-
tive coreceptors were tested in parallel with a subset of SIVsmm
Env pseudotype viruses.
Found at: doi:10.1371/journal.ppat.1001064.s004 (0.18 MB TIF)
Table S1 Punnett square analysis of CCR5 allele frequencies
among YNPRC animals.
Found at: doi:10.1371/journal.ppat.1001064.s005 (0.03 MB
DOC)
Table S2 Punnett square analysis of CCR5 allele frequencies
among TNPRC animals.
Found at: doi:10.1371/journal.ppat.1001064.s006 (0.03 MB
DOC)
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